

- [8] Chaudhuri JR, Mridula KR, Umamahesh M, Swathi A, Balaraju B, Bandaru VC. High sensitivity C-reactive protein levels in acute ischemic stroke and subtypes: a study from a tertiary care center. *Iran J Neurol*, 2013, 12:92-97.
- [9] Youn CS, Choi SP, Kim SH, Oh SH, Jeong WJ, Kim HJ, Park KN. Serum highly selective C-reactive protein concentration is associated with the volume of ischemic tissue in acute ischemic stroke. *Am J Emerg Med*, 2012, 30:124-128.
- [10] Idicula TT, Brogger J, Naess H, Waje - Andreassen U, Thomassen L. Admission C-reactive protein after acute ischemic stroke is associated with stroke severity and mortality: the 'Bergen Stroke Study'. *BMC Neurol*, 2009, 9:18.
- [11] Kuwashiro T, Sugimori H, Ago T, Kuroda J, Kamouchi M, Kitazono T; FSR Investigators. Predictive role of C reactive protein in stroke recurrence after cardioembolic stroke: the Fukuoka Stroke Registry. *BMJ Open*, 2013, 3:E003678.
- [12] Yeh KH, Tsai TH, Chai HT, Leu S, Chung SY, Chua S, Chen YL, Lin HS, Yuen CM, Yip HK. Comparison of acute versus convalescent stage high-sensitivity C-reactive protein level in predicting clinical outcome after acute ischemic stroke and impact of erythropoietin. *J Transl Med*, 2012, 10:6.
- [13] Kocer A, Canbulat C, Gozke E, Ilhan A. C-reactive protein is an indicator for fatal outcomes in first-time stroke patients. *Med Sci Monit*, 2005, 11:CR540-544.
- [14] Biffi A, Devan WJ, Anderson CD, Cortellini L, Furie KL, Rosand J, Rost NS. Statin treatment and functional outcome after ischemic stroke: case-control and meta-analysis. *Stroke*, 2011, 42:1314-1319.
- [15] Blanco - Rivero J, de Las Heras N, Martín - Fernández B, Cachafeiro V, Lahera V, Balfagón G. Rosuvastatin restored adrenergic and nitrenergic function in mesenteric arteries from obese rats. *Br J Pharmacol*, 2011, 162:271-285.
- [16] Hadi N, Mohammad BI, Ajeena IM, Sahib HH. Antiatherosclerotic potential of clopidogrel: antioxidant and anti-inflammatory approaches. *Biomed Res Int*, 2013:ID790263.

(收稿日期:2014-05-14)

· 临床医学图像 ·

间变性星形细胞瘤

doi: 10.3969/j.issn.1672-6731.2014.08.020

Anaplastic astrocytoma

YAN Xiao-ling

Department of Pathology, Tianjin Huanhu Hospital, Tianjin 300060, China (Email: ll934065@126.com)




图1 光学显微镜观察可见细胞核异型性、染色质深染,核仁不明显 HE染色 高倍放大 图2 光学显微镜观察显示,Ki-67抗原标记指数较高 免疫组织化学染色(EnVision二步法) 高倍放大

Figure 1 Optical microscopy findings showed nuclear atypia, deep staining, and only inconspicuous nucleoli. HE staining high power magnified Figure 2 Optical microscopy findings showed the Ki-67 labeling index was relatively high. Immunohistochemical staining (EnVision) high power magnified

间变性星形细胞瘤是弥漫性浸润的恶性星形细胞肿瘤,成人好发,发生于大脑半球,可能起源于WHO II级弥漫性星形细胞瘤,亦可能原发,通常无低度恶性原始病变,具有进展为胶质母细胞瘤的倾向。组织学特征与弥漫性星形细胞瘤基本相似,但细胞密度、核异型性、染色质深染和核分裂象增加(图1)。局灶性或弥漫性高细胞密度是诊断依据,即使细胞密度不增加,存在足够的核分裂象亦可明确诊断。伴进行性间变者核多形性更加复杂,胞核大小、形态不一,染色质密集或分散,核仁明显、数目增加;无微血管增生(多层血管)和坏死。与弥漫性星形细胞瘤相比,间变性星形细胞瘤Ki-67抗原标记指数升高(图2)。

(天津市环湖医院病理科阎晓玲供稿)